Every lab manager who has sat through a LIMS demo knows the feeling. The software looks brilliant. The presenter is sharp. And then you ask for a price, and the number that comes back has a second number hiding behind it — the one that actually decides whether the project survives the budget meeting.
Let's talk about that second number, because nobody puts it on the first slide.
The sticker price is the smallest part
Licensing is the cost you can see. It is also, for most labs, the minority of what you will eventually spend.
The working rule across the industry is that the total cost of ownership lands at roughly four to five times the software price once you add everything around it: implementation, configuration, validation, data migration, training, and the years of support that follow. A serious deployment is not a download. It is a project — commonly six to twelve months from kickoff to a validated, live system — and the people-hours in that project usually outweigh the licence.
So when you compare options, comparing licence fees alone is like buying a car on the price of the steering wheel. Ask instead: what does year one really cost, and what does each year after that look like?
The hidden lines on the quote
A few costs reliably surprise first-time buyers:
- Configuration versus customisation. Every vendor says the system is "configurable." The honest question is how much of your workflow fits the configuration, and how much needs custom development — which is slower, pricier, and harder to validate. Map your real workflow before the demo, not after the contract.
- Validation. In a regulated lab, an unvalidated system is just expensive software. IQ/OQ/PQ documentation, test scripts, and the qualification effort are real line items. Some include a validation package; some sell it separately; some leave it to you.
- Integration. Pulling results straight off your instruments is where a LIMS earns back its cost — and where projects quietly overrun. Each interface is its own small project. Count your instruments honestly.
- The renewal. The number that matters is not what you pay this year. It is what you pay in year three, after the discount lapses and the user count has grown.
The currency line nobody mentions in the brochure
Here is the part specific to running a lab in Egypt.
A contract priced in dollars is a moving target. The licence you sign today reprices itself at every renewal, and the exchange rate is not a variable you control. You end up defending a pound budget to a finance director against a cost that drifts upward on its own.
Being able to contract and pay in Egyptian pounds is not a minor convenience. It is the difference between a predictable line item and a recurring argument with finance every renewal cycle. Build that into the comparison from the start.
What you are actually buying it to do
Strip away the feature list and a LIMS in a regulated Egyptian lab has one job that dwarfs the rest: survive an inspection.
The Egyptian Drug Authority enforces WHO GMP, and its inspectors have grown noticeably more fluent in data integrity. The findings they write up are boringly consistent — and worth memorising, because they tell you exactly what the system has to enforce:
- Records completed after the fact instead of contemporaneously.
- Audit trails switched off, or switched on but never actually reviewed.
- Laboratory raw data not kept in its original form.
- CAPAs closed without anyone verifying the action worked.
- Training records that do not match what people actually do at the bench.
Read that list again. Not one of those is a missing feature. They are all enforcement failures — places where the system has to make the wrong thing impossible, not merely make the right thing available. That is what ALCOA+ means in daily practice, and it is the same expectation whether you trace it to the EDA, WHO TRS 1033, EU Annex 11, or 21 CFR Part 11. The references differ; the standard is identical.
Almost any serious LIMS can tick these boxes on paper. The real question is whether the people configuring yours understand what an Egyptian inspector will actually open and click during an audit. That is a competence question, not a licence question — and it is where the right implementation partner is worth more than any feature.
Four questions worth more than any demo
Before you fall for an interface, answer these honestly:
How much of our workflow genuinely fits the system as configured, versus needs custom work? What is year three going to cost, in pounds, not year one in dollars? Who validates it, and is that effort in the quote or extra? And when it goes down during a stability pull the week before an inspection, how fast can someone who knows our setup actually help?
Your answers will tell you more than any feature matrix. A LIMS is a ten-year relationship, not a purchase. Price it like one.
The market is moving in the buyer's favour
For a long time, lab software in this region meant importing an expensive platform built for someone else's regulatory world. That is changing. Middle East and Africa is still only about 5% of global LIMS spend, but it is growing at close to 10% a year as accreditation pressure climbs — and that growth is increasingly being met by systems built and supported locally. For the buyer, that is rare good news: more leverage, clearer pricing, and a partner in the same time zone.
Want a straight answer on what a LIMS will cost your lab?
Talk to a local CORPEX specialist about scope, validation, and pricing in EGP — in Arabic or English.
See CORPEX LIMS for Egypt
